Genmab — Januar 2023

[Riis7]

Tror jeg venter, sidste gang købte jeg for tidligt og vi endte i 1875, tror nemt vi kan se 2400 inden næste optur , fik heldigvis solgt i 3000+ hvilket jeg ikke fik i aug 2021 hvor
den faldt tilbage

[Riis7]

Men det er u

[Riis7]

Umuligt og ramme bund og top i Genmab så nok godt tidpunkt som du skriver hvis man tænker langsigtede:-)

[Sukkeralf]

https://endpts.com/jj-quietly-punts-a-pair-of-early-stage-bispecifics-for-solid-tumors/

[Sukkeralf]

Just a moment...

(www.fiercebiotech.com)

[Riis7]

Det virker til folk sælger ud af Pharma og over i tech i 2023

[Sukkeralf]

The other culled project, JNJ-8902, focused specifically on prostate cancer, with a phase 1 study looking to enroll more than twice as many patients as the JNJ-6358 trial. Recruitment wrapped up in September, and few updates have been posted since, except a pushback of the expected completion date from January 2023 to the end of June 2023. The trial was similarly not recruiting out of the U.S. but did include trial sites in Canada in addition to Israel and Spain.

[Sukkeralf]

JNJ-902 var vel et DuoBody BsAb

[E_L]

yes it was. it isn't a surprise as they stopped recruiting in september. it isn't completely dead, the trial continues with existing patients but i don't think we should expect anything anymore on it.

[E_L]

then again, i don't think you did if i remember correctly

[E_L]

JNJ's pipeline priorities https://jnj-content-lab.brightspotcdn.com/18/f6/b12412444e76b6f9775371de1dd0/jnj-pipeline-4q2022.pdf

[Sukkeralf]

No I remember we talked about this asset before so thats was kind of expected

[E_L]

another small Teclistamab in Combination with Daratumumab trial https://clinicaltrials.gov/ct2/show/NCT05695508

[ProinvestorNEWS]

Regnskabssæsonen - kontant afregning ved kasse 1
Regnskabssæsonen er for alvor i gang. Goldman Sachs, Tesla, Topdanmark, Tryg og Netcompany er oppe at vende. Derudover kommer Helge Larsen ind på pharma-, biotek- og laksesektoren.

Kort video: https://www.proinvestor.com/boards/109855

[E_L]

EPCORE DLBCL-2
started recruiting earlier this month https://clinicaltrials.gov/ct2/show/NCT05578976

[E_L]

Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma https://ascopost.com/issues/january-25-2023/study-shows-activity-of-talquetamab-in-highly-refractory-multiple-myeloma/

[bikube]

Jeg lod mig narre af "EPCORE_DLBCL 2". Det er fase 3.

[E_L]

and EPCORE DLBCL-3 is phase 2, just to make it easy for you

[bikube]

HaHa.

[E_L]

Case report: Relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement https://pubmed.ncbi.nlm.nih.gov/36699620/ "We add to existing limited data that Daratumumab penetrates the blood-brain barrier."